Latest Research And Development News

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Deep Yellow Limited reported a $10.6 million operating cash outflow for the September quarter but maintains a robust cash position with over $203 million on hand, supporting an estimated 14 quarters of funding.

Beetaloo Energy Australia Limited reported a robust cash position and secured new financing facilities to support ongoing development at its Carpentaria project. Despite significant exploration outflows, the company maintains sufficient liquidity to advance operations.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Saferoads Holdings Limited reported a solid quarterly profit of $346,000, driven by strong product sales including a key order from On-site Rentals. However, the company signals caution on sustaining profitability due to market uncertainties and inventory adjustments.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Advanced Braking Technology Ltd has kicked off FY26 with a 21% rise in product sales revenue and a 66% jump in net profit before tax, underpinned by expanding international demand and progress in autonomous braking systems.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

DroneShield Limited has delivered a blockbuster quarter with record revenue and operating cash flow, driven by new SaaS products and major government contracts. The company is positioning itself for sustained profitability and expansion into civilian markets.

Vectus Biosystems has had its ASX trading suspension lifted following the disclosure of a significant transaction involving a compound from its drug library, signaling renewed investor interest.